3 completed, 1 recruiting. 3 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 3 |
| Phase 2 | 1 | Recruiting 1 |
Follow Chengdu SciMount Pharmatech Co., Ltd.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SMP-656 for HER2-Positive Advanced Breast Cancer SMP-656 Injection - HER2-positive Breast Cancer, Metastatic Breast Cancer | Phase 2 | Recruiting | Chengdu SciMount Pharmatech Co., Ltd. | 60 | 2026-08-10 | 2026-10-15 |
| A First-in-human Study of SMP-656 in Subjects With Locally Advanced/ Metastatic HER2 Expressing or Mutated Solid Tumors SMP-656 Injection - HER2-Expressing Advanced Solid Tumors, HER2-Mutated Advanced Solid Tumors | Phase 1 | Completed | Chengdu SciMount Pharmatech Co., Ltd. | 35 | 2024-02-01 | 2026-11-06 |
| 3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability SMP-100 - Healthy Volunteers | Phase 1 | Completed | Chengdu SciMount Pharmatech Co., Ltd. | 8 | 2021-09-09 | 2022-03-11 |
| A Phase 1 Study of SMP-100 in Normal Healthy Volunteers SMP-100, Placebo - Healthy Volunteers | Phase 1 | Completed | Chengdu SciMount Pharmatech Co., Ltd. | 53 | 2020-06-25 | 2022-03-11 |
Breast Neoplasms (1)
Australia (2) · China (2)
Jian Zhang, MD (1) · Sepehr Shakib (1) · Thomas Polasek (1)